Last Price$301.78Cboe Real-Time Last Sale as of 2:55PM ET 6/03/20
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-1.08(0.36%)
Bid (Size)$301.53 (19)
Ask (Size)$301.87 (1)
Day Low / High$299.95 - 304.68
Volume473.5 K

View Biotechnology IndustryPeer Comparison as of 06/03/2020


Biogen Inc ( NASDAQ )

Price: $301.78
Change: -1.08 (0.36%)
Volume: 473.5 K
2:55PM ET 6/03/2020

Illumina Inc ( NASDAQ )

Price: $359.32
Change: -6.74 (1.84%)
Volume: 529.9 K
2:54PM ET 6/03/2020

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

Regeneron Pharmaceuticals Inc ( NASDAQ )

Price: $602.54
Change: -15.12 (2.45%)
Volume: 1.0 M
2:53PM ET 6/03/2020

Agilent Technologies Inc ( NYSE )

Price: $90.50
Change: +0.21 (0.23%)
Volume: 751.5 K
2:54PM ET 6/03/2020

Read more news Recent News

Vir Biotechnology, Biogen Finalize Deal for Production of SARS-CoV-2 Antibodies for Potential COVID-19 Treatment
8:37AM ET 5/29/2020 MT Newswires

Vir Biotechnology (VIR) said premarket Friday that it has finalized a deal with Biogen (BIIB) for the development and clinical manufacturing of SARS-CoV-2...

Analyst Actions: RBC Capital Cuts Biogen's Price Target to $303 From $310, Maintains Sector Perform Rating
7:46AM ET 5/29/2020 MT Newswires

Biogen's (BIIB) average rating among analysts is a hold, with an average price target of $317. Price: 300.50, Change: -0.96, Percent Change: -0.32 ...

Biogen Says Additional Data Show Sustained Efficacy, Safety of Spinraza in Patients With Spinal Muscular Atrophy
11:09AM ET 5/18/2020 MT Newswires

Biogen (BIIB) said Monday additional data showed the sustained efficacy and longer-term safety of Spinraza in various patients with spinal muscular...

Sangamo Therapeutics Narrows Q1 Loss on Higher Revenue, Reaffirms Operating Expense Targets
4:14PM ET 5/11/2020 MT Newswires

Sangamo Therapeutics (SGMO) on Monday narrowed its net loss to $0.37 per share in Q1 from $0.41 per share a year earlier, as revenue grew to $13.08 million...

View all Commentary and Analysis featured highlights include: Canadian Solar, Biogen, Graphic Packaging and Vistra Energy
8:42AM ET 6/03/2020 Zacks featured highlights include: Canadian Solar, Biogen, Graphic Packaging and Vistra Energy

Biogen: Strong Current Cash Flow, Exciting Growth Opportunities
12:16PM ET 5/30/2020 Seeking Alpha

Screening For Growth Leaders With Outstanding Profitability
4:14PM ET 5/29/2020 Seeking Alpha

Healthcare And Biotechnology Dashboard - Update
7:03PM ET 5/26/2020 Seeking Alpha

Company Profile

Business DescriptionBiogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA. View company web site for more details
Address225 Binney Street
Cambridge, Massachusetts 02142
Number of Employees7,800
Recent SEC Filing04/30/20208-K
Chief Executive Officer & DirectorMichel Vounatsos
Chief Financial Officer & Executive Vice PresidentJeffrey D. Capello
Chief Medical Officer & EVP-Research & DevelopmentAlfred W. Sandrock
Chief Information Officer & Senior Vice PresidentMark Hernon

Company Highlights

Price Open$303.04
Previous Close$302.86
52 Week Range$215.78 - 374.99
Market Capitalization$49.2 B
Shares Outstanding163.2 M
SectorHealth Technology
Next Earnings Announcement07/28/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings9.48
Earnings per Share$33.22
Beta vs. S&P 500N/A
Revenue$12.1 B
Net Profit Margin45.96%
Return on Equity44.50%

Analyst Ratings as of 05/24/2020

Consensus RecommendationConsensus Icon
Powered by Factset